Prescription practice of antihistamines for acute upper respiratory tract infections in pediatric patients in a local emergency department in Hong Kong

Chun Tat Lui
Department of Accident and Emergency Medicine, Tuen Mun Hospital, Hong Kong, China

Corresponding Author: Chun Tat Lui, Email: ectlui@yahoo.com.hk

BACKGROUND: Currently there is very limited data in the literature assessing the prevalence of antihistamine prescription, and there is no local prevalence data about the prescription of antihistamine agents among primary practitioner and emergency physicians. The objectives are 1) to report the prevalence of antihistamine prescription for children less than 6 years old with acute upper respiratory infection and 2) to explore the associated factors for the prescription practice.

METHODS: This is a cross-sectional study. All consecutive cases of paediatric patients aged 6 or below who presented to the emergency department during a study period of one week from April 1 to July 4, 2009 with diagnosis of acute upper respiratory infection were included. Totally 162 patients were included.

RESULTS: Among the 162 cases, 141 (87%) patients were prescribed one antihistamine of any group. Sixty (37%) patients were prescribed two or more antihistamines. In multivariate logistic regression model, age was found to be significantly ($P<0.001$) associated with multiple antihistamine prescription ($OR=1.042$, $95\% CI=1.02$ to $1.06$). Years of graduation of attending physician for more than 5 years was also a strong predictor of multiple antihistamine prescription ($OR=4.654$, $95\% CI=2.20$ to $9.84$, $P<0.001$).

CONCLUSION: In the local emergency department, patients’ age and the years of graduation from medical school of the attending physician were predictors of multiple antihistamine prescription for acute upper respiratory infections for children aged less than 6.

KEY WORDS: Upper respiratory infections; Respiratory tract infections; Common cold; Drug prescription; Drug utilization; Prescription practice; Antihistamine; Histamine antagonist; Children

INTRODUCTION
Acute upper respiratory infections (URI), including common cold, is one of the most prevalent infectious diseases in humans. Although the disease is usually mild and self-limiting, symptoms may last for one to two weeks and it is one of the leading causes of doctor visits and missed days from school and work with enormous economic impact. On average, adults suffer from about two to four colds a year, whereas children have about six to ten episodes. [1] According to the U.S. Centers for Disease Control and Prevention, 22 million school days are lost annually due to upper respiratory infections. [2]

Most of the upper respiratory infections are viral in origin. The commonly identified culprit viruses were rhinovirus, adenovirus, coronavirus, influenza virus, respiratory syncytial virus, parainfluenza virus and metapneumovirus. [3] There is currently no targeted antiviral for URI. Various medications currently available in the market are mainly for alleviation of symptoms but had not been associated with shortening of symptoms.
Commonly used medications include antipyretics, antihistamines and alpha-adrenergic agonist. The use of antipyretics had evidence of effectiveness in all age groups. Decongestants and perhaps decongestant/antihistamine combinations in adolescents and adults had scientific evidence to show modest benefit to reduce rhinorrhea, sneezing and nasal obstruction in first 2 days. First generation antihistamines have shown favorable effects upon nasal symptoms in some of the adult studies, probably because of their anti-cholinergic effects. However, the use of common cold preparations including antihistamines in children aged younger than 5 is not evidence-based. In the current primary practice in the locality and worldwide, prescription of common cold medications and antihistamines are very common, particularly in the private practice. In a survey by English et al, 26% of patients younger than age 5 were given a prescription that was not evidence-based and potentially harmful. Most of the prescriptions were extrapolation from the evidence in the adults. The unnecessary medication prescription had also significant cost implication and accounted for 60% of the total prescription cost in a family practice clinic. In Hong Kong, prescription of antihistamine was nearly universal among primary practice, and prescription of double, or even triple antihistaminergic agents for URI was common. The potential adverse side effects, risks and complications may probably be additive or synergistic for multiple simultaneous antihistamine ingestion.

Common cold medication had some evidence for symptomatic relief for adults with URI, through the benefit may be outweighed by the adverse side effects and potential risks. For the paediatric age group, systematic review had shown that use of antihistamine would have modest effect on relief of nasal symptoms in first 2 days but not in mid or long term symptoms. Furthermore, the use of common cold medications such as codeine may be associated with adverse drug effects and even mortality. The frequency of adverse effects of antihistamines in pediatric patients were not well studied. It may be crucial to evaluate the current prescription practice of the frontline doctors, the prevalence of antihistamine prescription, and explore the associated factors for antihistamine prescription. Currently there is very limited data in the literature assessing the prevalence of antihistamine prescription, and there is no local prevalence data about the prescription of antihistamine agents among primary practitioner and emergency physicians.

The primary objective is to report the prevalence of antihistamine prescription, and prescription of multiple antihistamines for URI in paediatric age group by emergency physician in a regional hospital. The second objective is to review prescription practice and behavior of emergency physicians about antihistamines and explore the possible associated factors affecting antihistamine prescription.

**METHODS**

This retrospective study was conducted in the Accident and Emergency Department (AED) of Tuen Mun Hospital, which is a regional hospital in Hong Kong. The regional hospital served a population of above a million people living in the New Territories region of Hong Kong and had a diversified clientele with daily AED attendance of about 600 patients. About a quarter of the patients were in the paediatric age group (aged less than 18). Upper respiratory infections were one of the most commonly encountered clinical problem in the emergency department. In our study, all consecutive cases of paediatric patients aged 6 or below who presented to the AED during a study period of one week from April 1 to July 4, 2009 with diagnosis of acute upper respiratory infection were included. The eligible cases were searched from the hospital electronic record database by the Clinical Data Analysis & Reporting System (CDARS), which is a computerized data retrieval system of the Hospital Authority of Hong Kong utilizing International Classification of Disease Coding, Ninth edition (ICD-9). We searched the diagnosis under the categories of principal and secondary diagnoses. The included ICD-9 codes were 462 (acute pharyngitis), 463 (acute tonsillitis), 381 and 382 (acute otitis media), 460 (acute rhinopharyngitis), 465, 465.9 and 212.9 (non-specific upper respiratory infection). All patients aged more than 6 years were excluded. Patients with diagnosis of acute bronchitis, chronic nasopharyngitis and allergic rhinitis were excluded. Patients who were admitted to hospital in the same attendance and those with labeled history of drug allergy to antihistamines were also excluded. All patients with other medical conditions that justify the use of antihistamines were also excluded. Relevant clinical information were collected from electronic patient record and written clinical record. All case records were retrieved and then reviewed by the principle investigator.

The primary outcome variable was multiple antihistamine prescription which was defined as prescription of more than one antihistamine. Patients
were classified as case group (multiple antihistamine was prescribed) and the control group (multiple antihistamine was not prescribed). The predicting factors variables to examine could be grossly classified into patient and physician factors. The patient factors included age (in months), gender, significant past medical history that warranted long term follow-up by paediatrician or specialist, whether this was a reattendance case (reattendance being defined as reattendance to the AED within 48 hours for similar chief complaint), and the number of antihistamines prescribed by the attending physician. Physician factors included whether the attending physician was a fellow in any specialty and the years of graduation from medical school. Relevant history of drug allergy was reviewed and those with labeled allergy to any antihistamines were excluded.

All variables were first screened through univariate analysis by Chi square test or Fisher's exact test for binary variables, and independent sample t-test for continuous variables. They were then included in the model of unconditioned logistic regression analysis with backward stepwise methodology based on likelihood ratios. Age and gender were also included as confounding variables. Likelihood ratio statistic was used to assess the goodness of fit of the model and level of significance was taken at 5%. The statistical package employed was SPSS 16.0.

There is no epidemiological study in the literature to provide suitable reference on sample size planning. We therefore planned our sample size by assuming a power of 90%, a significance level of 5%, baseline response probability as 0.4 to detect a moderate effect size of odds ratio=3 or higher. An adjustment of regression of one independent variable on the other was made and $R^2$ was assumed to be 0.75. The total sample size (case plus control) required would be 145 as calculated by PASS 2008 Software by NCSS, US.

Ethical approval was exempted with the retrospective study. The study process had been compliant to the principles in the Declaration of Helsinki.

RESULT

A total of 171 eligible cases were retrieved by CDARS. After reviewing the case notes, 8 cases of coexisting medical conditions that warranted antihistamine prescription (eczema, allergic rhinitis) and one case of labeled allergy to chlorpheniramine were excluded. All the remaining 162 cases were included in the final analysis.

Among the 162 cases, 141 (87%) patients were prescribed one antihistamine of any group, while 60 (37%) patients were prescribed two or more antihistamines (Figure 1).

For analyzing factors associated with multiple antihistamine prescription, the occurrences of studying parameters for both case and control groups were shown in Table 1. For univariate analysis, only patient age and attending physician year of graduation from medical school ≥5 years showed statistical significant differences. For the patient group that was prescribed multiple antihistamines, the mean age was 42.7 months compared to the mean age of control group was 29.1 months. For the case group, percentage of attending doctors who graduated from medical school for more than 5 years was 73.3%, compared to the same covariate of 39.2% in the control group.

All of the variables were put into the logistic regression model to adjust for potential confounding (Table 2). Age was found to be significantly ($P<0.001$) associated with multiple antihistamine prescription ($OR=1.042$, 95% CI=1.02 to 1.06). There was observed trend of

![Figure 1. Prevalence of antihistamine prescription for URI in children aged <6.](image)

<table>
<thead>
<tr>
<th>Table 1. Univariate analysis for predicting factors of prescription of multiple antihistamines in paediatric URI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Predictive factors</td>
</tr>
<tr>
<td>Chronic diseases, $n$ (%)</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Reattendance, $n$ (%)</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Age (mean±SD) (months)</td>
</tr>
<tr>
<td>Chronic diseases, $n$ (%)</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Attending physician years of graduation ≥5 years, $n$ (%)</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
</tbody>
</table>
increasing prevalence of antihistamine prescription with higher age group (Figures 2 and 3). Years of graduation of attending physician for more than 5 years was also a strong predictor of multiple antihistamine prescription ($OR=4.654, 95\%CI=2.20$ to $9.84, P<0.001$).

For the model calibration and goodness of fit, which refers to the agreement in the individual patients between the predicted risks as assigned by the model and the actual observed frequencies, this was evaluated with the Hosmer-Lemeshow test, which if significant indicates poor model fit. In the finalized logistic regression model that integrated patient age and years of graduation of attending physician, the Hosmer-Lemeshow test was insignificant ($P=0.755$), hence indicating good fitting of the model.

**DISCUSSION**

In Hong Kong, the concept of family doctor and primary care was not yet familiarized by many of the general public and URI remains to be one of the most commonly encountered clinical problem in emergency department in Hong Kong, which accounts up to 10%–20% of the case-mix in the local emergency departments, including the paediatric age group.$^{[5,6]}$ In other words, emergency department served as part of the public primary care units in Hong Kong, particularly after opening hours of the General Outpatient Clinics (GOPC). Currently there was no local clinical audit nor quality assurance program about the use of common cold medications including antihistamines for URI within emergency department or primary care clinic in Hong Kong.

Antihistamine and other common cold medications are commonly used for URI in Hong Kong, both in over-the-counter medications and doctors’ prescription, including in the primary care clinic and emergency department. A survey conducted by Centers for Disease Control and Prevention in 1994 showed that two-thirds of three-year-old had taken cough or cold medicine in the preceding 30 days.$^{[9]}$ In a recent review in 2008 in United States, approximately 1 in 10 US children uses a cough and cold medication in a given week. The especially high prevalence of use among children of young age of less than 5 is noteworthy, given concerns about potential adverse effects and the lack of data on the efficacy of cough and cold medications in this age group.$^{[10]}$

There was no local report or survey in Hong Kong. The problem may be particularly important in Hong Kong because the use of over-the-counter medication, frequent prescription of antihistamines and other common cold medications by general practitioner, frequent doctor-shopping behavior of parents and possible overdosage of

---

**Table 2. Multivariate logistic regression analysis for multiple antihistamine prescription**

<table>
<thead>
<tr>
<th>Predictive variables</th>
<th>Percent of antihistamine prescription</th>
<th>Number of antihistamine prescription</th>
<th>Odds ratio</th>
<th>95%CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean±SD) [months]</td>
<td>1.042</td>
<td>1.02–1.06</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Controls: 29.1±18.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>0.161</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>30.4</td>
<td>24/79</td>
<td>0.56</td>
<td>0.27–1.18</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>43.4</td>
<td>36/83</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic disease</td>
<td>0.099</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>55.6</td>
<td>5/9</td>
<td>3.63</td>
<td>0.75–17.5</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>35.9</td>
<td>55/153</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reattendance</td>
<td>0.365</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>40</td>
<td>2/5</td>
<td>0.445</td>
<td>0.06–3.57</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>36.9</td>
<td>58/157</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attending physician years of graduation from medical school ≥5 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Yes</td>
<td>52.3</td>
<td>44/84</td>
<td>4.654</td>
<td>2.20–9.84</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>20.5</td>
<td>16/78</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attending physician was as fellow</td>
<td>0.711</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>48.3</td>
<td>14/29</td>
<td>0.848</td>
<td>0.31–2.33</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>34.6</td>
<td>46/133</td>
<td>1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Antihistamines are heterogeneous groups of compounds with various side effects. Use of antihistaminergic agents is not without risks. As reported by the Centre for Disease Control (CDC), approximately 7 100 patients aged under 12 years were treated in emergency departments for adverse drug events from cough and cold medicines in children in US.\textsuperscript{[15–20]} Antihistamines are commonly known to have depressant effects on the central nervous system, although occasional paradoxical stimulant effects had been reported, particularly among children. These include tremor, insomnia, irritability, hallucinations and seizure.\textsuperscript{[21,22]} Although diphenhydramine has been used for treating oculogyric crisis and acute dystonic reactions, dystonia had been reported following use of antihistamine such as chlorpheniramine and diphenhydramine.\textsuperscript{[23–29]} The exact mechanism is not well defined, but several hypothesis have been proposed. Diphenhydramine is a phenothiazine derivatives and phenothiazine had antidopaminergic activity, causing imbalance in central cholinergic and dopaminergic neurotransmission.\textsuperscript{[30]} Other hypothesis include rebound increases in nigral inhibition of the basal ganglia and involvement of the aminobutyric acid neurotransmitter system have been postulated.\textsuperscript{[30–32]} Furthermore, apparent life-threatening events have been associated with use of common cold medications.\textsuperscript{[33]} In January 2007, the CDC published a report describing three deaths of infants aged <6 months of age for which cough and cold medications were determined to be the underlying cause of death.\textsuperscript{[34]} From the Adverse Event Reporting System (AERS) of the US Food and Drug Administration (FDA), 69 fatalities in the paediatric age group was associated with the use of antihistamines were identified: diphenhydramine 33, brompheniramine 9 and chlorpheniramine 27. Of these 69 fatalities, 49 occurred in children aged <2 years and 28 in children aged 2–6 years.\textsuperscript{[35]} Overdose and drug toxicity were commonly reported adverse events. The reasons given for the overdose occurring included use of multiple cough/cold products, medication errors, accidental exposures and intentional overdoses. There is consensus with expert opinion and evidence-based medicine to support that the risk outweighed the benefit for the use of antihistamines and other common cold medications for treatment of URI in children.\textsuperscript{[36]} In addition, FDA had issued a black box warning in 2006 against the use of promethazine in children less than 2 years old.

With more evidence of lacking efficacy of antihistamines in children with URI, and more reports of adverse drug events and complications associated with antihistamine use, there is raising concerns in recent years about the safety and efficacy of cough and cold medications in children. In 2006, the American College of Chest Physicians found that "literature regarding over-the-counter cough medications including antihistamines does not support the efficacy of such products in the pediatric age group".\textsuperscript{[37]} The American Academy of Pediatrics (AAP) considered that there was sufficient

Table 3. Trials evaluating efficacy of antihistamines in treating symptoms of URI in children

<table>
<thead>
<tr>
<th>Drug</th>
<th>Age group</th>
<th>Study</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brompheniramine + phenylephrine vs. placebo</td>
<td>Less than 6 years old</td>
<td>Hutton et al\textsuperscript{[35]}</td>
<td>No significant difference</td>
</tr>
<tr>
<td>Brompheniramine + phenylpropanolamine vs. placebo</td>
<td>Less than 6 years old</td>
<td>Clemens et al\textsuperscript{[16]}</td>
<td>No significant difference</td>
</tr>
<tr>
<td>Chlorpheniramine vs. clematine vs placebo</td>
<td>Less than 6 years old</td>
<td>Sakchainanont et al\textsuperscript{[17]}</td>
<td>No significant difference</td>
</tr>
<tr>
<td>Diphenhydramine vs. dextromethorphan vs. placebo</td>
<td>2 to 16.5 years old (median 4.5 years old)</td>
<td>Paul et al\textsuperscript{[18]}</td>
<td>No significant difference</td>
</tr>
<tr>
<td>Diphenhydramine vs. dextromethorphan vs. placebo</td>
<td>2 to 16.5 years old (median 7.5 years old)</td>
<td>Yoder et al\textsuperscript{[19]}</td>
<td>No significant difference</td>
</tr>
</tbody>
</table>
available data from paediatric studies to conclude that
cough and cold medicines are ineffective in children. In
addition, the AAP noted that although these medicines
are generally safe when used according to the product
labelling, there are two situations that potentially put
children at risk of serious adverse events or death
when exposed to cough and cold medicines: the first
is inappropriate dosing of cough and cold medicines.
The AAP considers that the available of multiple multi-
ingredient preparations that may contain the same active
ingredients contributes to this risk. Secondly, complete
lack of data to support current dosing regimens for
paediatric patients. The lack of information available
to physicians when the product labeling recommends
consulting a physician for dosage advice. In addition
there is possible risk with drug interaction between
new generation antihistamine and macrolide to cause
prolonged QTc-related arrhythmia. The AAP is also
concerned that children under 2 appear to have a greater
sensitivity to the potentially fatal effects of some of the
ingredients in cough and cold medicines. The AAP
considered that extrapolation of adult efficacy data for
children is not justifiable as available paediatric data do
not support the efficacy of these medicines. In addition,
there is significant age-related developmental variability
in both pharmacokinetics and pharmacodynamics in
children such that it is clear that adults and children
handle and respond to drugs differently. The AAP
expressed considerable concern at the demonstrable
lack of efficacy, evidence for considerable misuse, lack
of rational basis for dosing, and apparent increased
sensitivity to toxicity of these preparations in children
under 6 years of age. The AAP recommended that unless
clear, evidence-based paediatric dosing guidelines are
available for all ages, these products should not be
available for over-the-counter use in these age groups.
The American Academy of Family Physicians (AAFP)
considered that it is inappropriate to extrapolate adult
efficacy data to children. The AAFP noted that serious
complications are rare when the medications are used
correctly, and supported the advice issued by the FDA to
parents and caregivers in the Public Health Advisory.

Current advice from the National Health Service
(NHS) of United Kingdom on treating colds and coughs
in children includes giving fluids and treating fever and
pain with paracetamol or ibuprofen, and the use of saline
drops to loosen dried nasal secretions or help a stuffy
nose in young children and babies. Although steam
inhalation is not suitable for children because of the risk
of scalding, a child may benefit from sitting in a hot,
steam. Simple cough mixtures containing a
demulcent, for example glycerin, and syrup can have a
soothing effect by coating the throat and relieving the
irritation which causes the cough; a child over the age of
one may also be helped by a warm drink of lemon and
honey.\[38\]

In the study, it was demonstrated that younger
doctors tends to prescribe less antihistamines for
children with URI. We hypothesized that this may be
attributable to the emphasis of the risks-benefit ratio of
antihistamines in pediatric URI in the undergraduate
curriculum in medical schools. This contrasted to the
need of change in practice and prescription behaviour for
older doctors where they had already developed habits
of prescription. This may provide insights on the way on
further educational strategies to tackle the problem of
overuse of antihistamines.

In Hong Kong, the Department of Health had not
issued formal recommendation or advisory statements
on the use of cold medications and antihistamine for
children with URI. Furthermore, there was no regulation
about the labelling of the common over-the-counter cold
medications about the caution while using in children.
With high rate of doctor shopping behaviour of parents
in Hong Kong, children are more likely to expose to
various cold medications and multiple antihistamines.
Since the effect may be additive or synergistic, this
may result in dosing error or overdose, increasing the
risk of complications or unexpected death, and cases
of unexpected mortality of children with URI were
reported to be associated with antihistamine and other
cold medication use in Hong Kong. Our study provided a
recent review of the prevalence data about antihistamine
prescription for URI in children in a local emergency
department setting. While for very young infants, the
emergency physicians are quite cautious to prescribe
antihistamines, but for the toddlers and older children
prescription of multiple antihistamines is quite common.
More focus should be put on the publication of the concept
of higher potential risks of antihistamine use in children
aged less than 6. Moreover, doctors who graduated
longer from medical schools have higher rate of multiple
antihistamine prescription. With further understanding
of the factors affecting prescription practice, targeted
interventions and educational program could be designed
for both primary care physicians, emergency physicians
and the public, to reduce the unnecessary prescription of
antihistamine and avoid potential risks. A local taskforce
for reviewing the current evidence, provide advisory and
recommendation, setting up plans for public education,
undergraduate curriculum and postgraduate education of frontline doctors is necessary.

Limitation of the study
The sampling method included pediatric URI patients in one week in first week of April 2009. There is potential selection bias with the sampling method. Furthermore, the antihistamine prescription time from symptom onset were not investigated in the study. There may be potential symptomatic benefit for those presented within 2 days.

CONCLUSION
In the local emergency department, the prevalence of prescription of single and multiple antihistamines for URI in children aged less than 6 were 87% and 37% respectively. Patient's age and the years of graduation from medical school of the attending physician are significant predictors of multiple antihistamine prescription. Further education of the public and recommendations to the emergency physician about cautious prescription of antihistamines and common cold medications for URI in children are necessary.

ACKNOWLEDGMENTS
The author thanks Professor Cheung Yiu-fai for his dedication and expert advice on the manuscript. The manuscript was a dissertation submitted for the Postgraduate Diploma in Child and Adolescent Health of the University of Hong Kong.

Funding: None.
Ethical approval: Ethical approval was exempted with the retrospective study.
Conflicts of interest: The author receives no financial support or has no financial interest in any of the devices or medication used in the studies.
Contributors: Liu CT proposed and wrote the study.

REFERENCES

38 National Health Service. Treating a common cold. assessed at http://www.nhs.uk/Conditions/Cold-common/Pages/Treatment.aspx.

Received March 29, 2016
Accepted after revision October 20, 2016